Evidence map›Paper›PMID 30962310›Full record

ArticleJournal of lipid research2019

Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation.

Su-Fern Tan, Wendy Dunton, Xin Liu, Todd E Fox, Samy A F Morad, Dhimant Desai, Kenichiro Doi, Mark R Conaway, Shantu Amin, David F Claxton and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of lipid research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Su-Fern TanDepartment of Medicine, Division of Hematology and Oncology University of Virginia School of Medicine, Charlottesville, VA.
Wendy DuntonDepartment of Medicine, Division of Hematology and Oncology University of Virginia School of Medicine, Charlottesville, VA.
Xin LiuPenn State Hershey Cancer Institute Hershey, PA.
Todd E FoxDepartments of Pharmacology University of Virginia School of Medicine, Charlottesville, VA.
Samy A F MoradDepartment of Pharmacology, Faculty of Veterinary Medicine, South Valley University, Qena, Egypt.
Dhimant DesaiDepartments of Pharmacology Pennsylvania State University College of Medicine, Hershey, PA.
Kenichiro DoiPediatrics Pennsylvania State University College of Medicine, Hershey, PA.
Mark R ConawayPublic Health Sciences University of Virginia School of Medicine, Charlottesville, VA.
Shantu AminDepartments of Pharmacology Pennsylvania State University College of Medicine, Hershey, PA.
David F ClaxtonPenn State Hershey Cancer Institute Hershey, PA.
Hong-Gang WangPediatrics Pennsylvania State University College of Medicine, Hershey, PA.
Mark KesterDepartments of Pharmacology University of Virginia School of Medicine, Charlottesville, VA.
Myles C CabotDepartment of Biochemistry and Molecular Biology Brody School of Medicine, East Carolina University, Greenville, NC.
David J FeithDepartment of Medicine, Division of Hematology and Oncology University of Virginia School of Medicine, Charlottesville, VA.
Thomas P LoughranDepartment of Medicine, Division of Hematology and Oncology University of Virginia School of Medicine, Charlottesville, VA tploughran@virginia.edu.
University of Virginia · USPenn State Milton S. Hershey Medical Center · USPennsylvania State University · USEast Carolina University · USUniversity of Virginia Cancer Center

Funding

Tissue Repository and Animal Models CoreP01CA171983 · NCI · UNIVERSITY OF VIRGINIA · PI LOUGHRAN, THOMAS P. · 2013 to 2024
$19.9M
NCI NIH HHS P01 CA171983
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. More than half of older AML patients fail to respond to cytotoxic chemotherapy, and most responders relapse with drug-resistant disease. Failure to achieve complete remission can be partly attributed to the drug resistance advantage of AML blasts that frequently express P-glycoprotein (P-gp), an ATP-binding cassette transporter. Our previous work showed that elevated acid ceramidase (AC) levels in AML contribute to blast survival. Here, we investigated P-gp expression levels in AML relative to AC. Using parental HL-60 cells and drug-resistant derivatives as our model, we found that P-gp expression and efflux activity were highly upregulated in resistant derivatives. AC overexpression in HL-60 conferred resistance to the AML chemotherapeutic drugs, cytarabine, mitoxantrone, and daunorubicin, and was linked to P-gp upregulation. Furthermore, targeting AC through pharmacologic or genetic approaches decreased P-gp levels and increased sensitivity to chemotherapeutic drugs. Mechanistically, AC overexpression increased NF-κB activation whereas NF-kB inhibitors reduced P-gp levels, indicating that the NF-kappaB pathway contributes to AC-mediated modulation of P-gp expression. Hence, our data support an important role for AC in drug resistance as well as survival and suggest that sphingolipid targeting approaches may also impact drug resistance in AML.

Indexed as

Acid CeramidaseAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily B, Member 1Blotting, WesternCell SurvivalCytarabineDaunorubicinDrug Resistance, NeoplasmFlow CytometryHEK293 CellsHL-60 CellsHumansIn Vitro TechniquesLentivirusLeukemia, Myeloid, AcuteMitoxantroneAcid CeramidaseAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily B, Member 1CytarabineDaunorubicinMitoxantroneNF-kappa Badenosine 5′-triphosphate binding cassette transporter B1cancerceramidedrug therapymultidrug resistance protein 1nuclear factor-κBsphingolipidsphingosine 1-phosphate

Identifiers

PMID30962310
PMCPMC6547629
OpenAlexW2938689433

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.